- Endo International (ENDP -3.3%) slips on below-average volume in apparent reaction to the Athenex's U.S. launch of its generic vasopressin, a diuretic that is Endo's top seller, accounting for almost 15% of its Q2 sales ($106.3/$714.7).
- Legal action is likely since Endo says compounding of vasopressin should not be allowed.
- Previously: Athenex launches vasopressin ready-to-use premix IV bags in U.S. (Aug. 13)
Endo under modest pressure on Athenex vasopressin launch, shares down 3%
Recommended For You
About ENDPQ Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
ENDPQ | - | - |
Endo International plc |